Thryv Therapeutics Licenses a New Class of SGK1 Inhibitors from Spain's CSIC and Universidad Autónoma de Madrid, Extending Its Platform into Neurodegenerative Disease
Exclusive worldwide license adds a structurally distinct SGK1 inhibitor scaffold to Thryv's portfolio, with claims spanning neurodegenerative and cardiovascular indications, creating a purpose-built path toward Parkinson's disease, Alzheimer's disease, and related disorders alongside the...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.